Changeflow GovPing Pharma & Drug Safety Lipid Nanoparticle Stem Cell Therapeutics - Eur...
Routine Rule Added Final

Lipid Nanoparticle Stem Cell Therapeutics - European Patent EP4330391A1

Favicon for changeflow.com EPO Patent Bulletin - Biotech (C12N)
Published
Detected
Email

Summary

The European Patent Office granted Patent EP4330391A1 to the Trustees of the University of Pennsylvania for compositions and methods targeting lipid nanoparticle therapeutics to stem cells. The patent covers IPC classifications including A61K 47/69, A61K 47/68, A61K 9/51, C12N 15/88, and A61K 48/00. The patent is valid in 35 designated European member states including Germany, France, the United Kingdom, Italy, and Spain.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The European Patent Office published EP4330391A1, a granted patent for compositions and methods targeting lipid nanoparticle therapeutics to stem cells. Inventors Hamideh Parhiz and Drew Weissman developed the technology, which falls under pharmaceutical and biotech IPC classifications. The patent provides intellectual property protection in 35 designated European states.

For biotech firms, pharmaceutical companies, and research institutions working with lipid nanoparticle delivery systems or stem cell therapies, this patent establishes IP rights that may affect freedom-to-operate assessments. Entities developing competing technologies or seeking licensing opportunities should review the patent claims and designated state coverage.

Archived snapshot

Apr 19, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

COMPOSITIONS AND METHODS FOR TARGETING LIPID NANOPARTICLE THERAPEUTICS TO STEM CELLS

Publication EP4330391A1 Kind: A1 Apr 08, 2026

Applicants

The Trustees of the University of Pennsylvania

Inventors

PARHIZ, Hamideh, WEISSMAN, Drew

IPC Classifications

A61K 47/69 20170101AFI20260303BHEP A61K 47/68 20170101ALI20260303BHEP A61K 9/51 20060101ALI20260303BHEP C12N 15/88 20060101ALI20260303BHEP A61K 48/00 20060101ALI20260303BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4330391A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Patent licensing IP management Biotech research
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Medical Devices Biotechnology

Get alerts for this source

We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!